The arrival of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable buzz within the medical community. This novel dual GIP and GLP-1 receptor medication suggests to offer impressive improvements in body shedding compared to current therapies. Preliminary patient studies have shown s